An update on adverse drug reactions related to β-lactam antibiotics

Area of Science:

• Pharmacology
• Clinical Medicine
• Drug Safety

Background:

• Beta-lactam antibiotics are frequently associated with drug-related adverse events.
• Immediate hypersensitivity reactions are a significant concern, though emerging evidence suggests they are less common than previously thought.
• Understanding specific cross-reactivity risks and agent-specific toxicities is crucial for safe beta-lactam use.

Purpose of the Study:

• To review the current understanding of adverse events associated with beta-lactam antibiotics.
• To evaluate the incidence and risk factors for hypersensitivity reactions and cross-reactivity.
• To discuss the relationship between antibiotic levels, dosage, and adverse event emergence.

Main Methods:

• Literature review of studies on beta-lactam adverse events.
• Analysis of emerging evidence on hypersensitivity and cross-reactivity.
• Expert opinion synthesis on factors influencing toxicity.

Main Results:

• Immediate hypersensitivity reactions to beta-lactams are less frequent than presumed; specialist evaluation is recommended before allergy diagnosis.
• Cross-reactivity risks are lower than previously estimated and often depend on specific side chains or metabolites.
• Agent-specific factors, rather than dose alone, appear to influence adverse events like organ toxicity and infections, with antibiotic levels being a key determinant.

Conclusions:

• Judicious selection and proper dosing of beta-lactams generally lead to mild adverse events.
• The risk of severe reactions and cross-reactivity is often overestimated, necessitating careful patient assessment.
• Antibiotic levels, alongside patient-specific factors, are critical in managing beta-lactam-associated adverse events, some of which can lead to significant morbidity or mortality.